DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DOCS - US26622P1075 - Common Stock
41.26 USD
+0.21 (+0.51%)
41.26 USD
0 (0%)
Overall DOCS gets a fundamental rating of 7 out of 10. We evaluated DOCS against 35 industry peers in the Health Care Technology industry. DOCS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. DOCS is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, DOCS could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
- DOCS had positive earnings in the past year.
- In the past year DOCS had a positive cash flow from operations.
- In the past 5 years DOCS has always been profitable.
- In the past 5 years DOCS always reported a positive cash flow from operatings.
1.2 Ratios
- DOCS's Return On Assets of 20.13% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
- DOCS's Return On Equity of 23.10% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
- DOCS has a Return On Invested Capital of 18.16%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for DOCS is significantly above the industry average of 6.63%.
- The last Return On Invested Capital (18.16%) for DOCS is above the 3 year average (14.17%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROIC | 18.16% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
- DOCS's Profit Margin of 40.72% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
- DOCS's Profit Margin has improved in the last couple of years.
- DOCS has a Operating Margin of 39.72%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
- DOCS's Operating Margin has improved in the last couple of years.
- The Gross Margin of DOCS (90.20%) is better than 97.14% of its industry peers.
- In the last couple of years the Gross Margin of DOCS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so DOCS is creating value.
- The number of shares outstanding for DOCS has been increased compared to 1 year ago.
- DOCS has more shares outstanding than it did 5 years ago.
- DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- DOCS has an Altman-Z score of 31.07. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of DOCS (31.07) is better than 100.00% of its industry peers.
- There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 31.07 |
ROIC/WACC1.87
WACC9.72%
2.3 Liquidity
- DOCS has a Current Ratio of 7.79. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of DOCS (7.79) is better than 91.43% of its industry peers.
- DOCS has a Quick Ratio of 7.79. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of DOCS (7.79) is better than 91.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 46.43% over the past year.
- DOCS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 79.21% yearly.
- The Revenue has grown by 20.21% in the past year. This is a very strong growth!
- The Revenue has been growing by 37.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
3.2 Future
- The Earnings Per Share is expected to grow by 14.75% on average over the next years. This is quite good.
- Based on estimates for the next years, DOCS will show a quite strong growth in Revenue. The Revenue will grow by 11.49% on average per year.
EPS Next Y14.22%
EPS Next 2Y11.46%
EPS Next 3Y11.79%
EPS Next 5Y14.75%
Revenue Next Year14.06%
Revenue Next 2Y12.59%
Revenue Next 3Y12.01%
Revenue Next 5Y11.49%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- DOCS is valuated quite expensively with a Price/Earnings ratio of 25.16.
- DOCS's Price/Earnings ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 80.00% of the companies in the same industry.
- DOCS's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.38.
- The Price/Forward Earnings ratio is 23.55, which indicates a rather expensive current valuation of DOCS.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 71.43% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of DOCS to the average of the S&P500 Index (24.29), we can say DOCS is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.16 | ||
| Fwd PE | 23.55 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, DOCS is valued a bit cheaper than the industry average as 65.71% of the companies are valued more expensively.
- 71.43% of the companies in the same industry are more expensive than DOCS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.89 | ||
| EV/EBITDA | 23.9 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- The excellent profitability rating of DOCS may justify a higher PE ratio.
PEG (NY)1.77
PEG (5Y)0.32
EPS Next 2Y11.46%
EPS Next 3Y11.79%
5. Dividend
5.1 Amount
- DOCS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
41.26
+0.21 (+0.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-05 2026-02-05/amc
Inst Owners91.38%
Inst Owner Change0.59%
Ins Owners1.96%
Ins Owner Change0.19%
Market Cap7.77B
Revenue(TTM)621.33M
Net Income(TTM)253.03M
Analysts77.86
Price Target66.64 (61.51%)
Short Float %5.99%
Short Ratio3.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.98%
Min EPS beat(2)16.41%
Max EPS beat(2)17.55%
EPS beat(4)4
Avg EPS beat(4)25.31%
Min EPS beat(4)16.41%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)23.42%
EPS beat(12)12
Avg EPS beat(12)22.47%
EPS beat(16)16
Avg EPS beat(16)28.98%
Revenue beat(2)2
Avg Revenue beat(2)3.67%
Min Revenue beat(2)2.52%
Max Revenue beat(2)4.82%
Revenue beat(4)4
Avg Revenue beat(4)4.22%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)7
Avg Revenue beat(8)3.68%
Revenue beat(12)9
Avg Revenue beat(12)2.53%
Revenue beat(16)12
Avg Revenue beat(16)2.69%
PT rev (1m)-4.51%
PT rev (3m)-6.07%
EPS NQ rev (1m)-0.1%
EPS NQ rev (3m)0.03%
EPS NY rev (1m)0.18%
EPS NY rev (3m)4.31%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)1.12%
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)1.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.16 | ||
| Fwd PE | 23.55 | ||
| P/S | 12.5 | ||
| P/FCF | 24.89 | ||
| P/OCF | 24.3 | ||
| P/B | 7.09 | ||
| P/tB | 8 | ||
| EV/EBITDA | 23.9 |
EPS(TTM)1.64
EY3.97%
EPS(NY)1.75
Fwd EY4.25%
FCF(TTM)1.66
FCFY4.02%
OCF(TTM)1.7
OCFY4.12%
SpS3.3
BVpS5.82
TBVpS5.16
PEG (NY)1.77
PEG (5Y)0.32
Graham Number14.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROCE | 22.1% | ||
| ROIC | 18.16% | ||
| ROICexc | 85.05% | ||
| ROICexgc | 177.37% | ||
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% | ||
| FCFM | 50.23% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score9
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 64.81% | ||
| Cap/Sales | 1.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 123.66% | ||
| Profit Quality | 123.35% | ||
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 | ||
| Altman-Z | 31.07 |
F-Score9
WACC9.72%
ROIC/WACC1.87
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
EPS Next Y14.22%
EPS Next 2Y11.46%
EPS Next 3Y11.79%
EPS Next 5Y14.75%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
Revenue Next Year14.06%
Revenue Next 2Y12.59%
Revenue Next 3Y12.01%
Revenue Next 5Y11.49%
EBIT growth 1Y22.24%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year17.72%
EBIT Next 3Y13.76%
EBIT Next 5Y14.23%
FCF growth 1Y94.7%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y93.3%
OCF growth 3Y29.24%
OCF growth 5Y59.83%
DOXIMITY INC-CLASS A / DOCS FAQ
What is the fundamental rating for DOCS stock?
ChartMill assigns a fundamental rating of 7 / 10 to DOCS.
What is the valuation status for DOCS stock?
ChartMill assigns a valuation rating of 4 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Fairly Valued.
How profitable is DOXIMITY INC-CLASS A (DOCS) stock?
DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.
What are the PE and PB ratios of DOXIMITY INC-CLASS A (DOCS) stock?
The Price/Earnings (PE) ratio for DOXIMITY INC-CLASS A (DOCS) is 25.16 and the Price/Book (PB) ratio is 7.09.
What is the earnings growth outlook for DOXIMITY INC-CLASS A?
The Earnings per Share (EPS) of DOXIMITY INC-CLASS A (DOCS) is expected to grow by 14.22% in the next year.